Indication

HRR Gene Mutation

1 clinical trial

1 product

2 drugs

Clinical trial

A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation

Status: Recruiting, Estimated PCD: 2024-06-30

Drug

Product

Drug